



1-800-533-1710

KRAS Somatic Mutation Analysis

KRASP

PATIENT NAME TESTINGKRASP, NORMAL				ORDER NUMBER K302000020
PATIENT ID R064475	DATE OF BIRTH 01/01/1991	AGE 30 Y	SEX Female	REQUESTED BY CLIENT CLIENT
COLLECTED 2/2/2021, 12:00 AM	RECEIVED 2/2/2021, 10:40 AM	REPORTED 2/18/2021, 12:53 PM		
The collected, received, and reported dates and times on the report are in the time zone of the performing location.				CLIENT ORDER NUMBER
VALIDC Test Validation's MML 35 characters City MN 123456789				CLIENT MRN R064475

RESULT SUMMARY

NEGATIVE

RESULT

Provided diagnosis: metastatic lung adenocarcinoma involving the brain

KRAS status: Wild-type

INTERPRETATION

Current data suggest that the efficacy of EGFR-targeted therapies in non-small cell lung cancer is limited to patients with tumors lacking KRAS mutations. Thus, the absence of a detectable KRAS mutation within this tumor specimen suggests that this patient may respond to such therapies. Consider additional testing (LNGPR / Lung Panel with Rearrangement Tumor) to rule out the presence of other mutations in KRAS or other genes that could impact therapeutic response.

SPECIMEN

Tissue, Tumor

TISSUE ID

1234

METHOD

Microscopic examination was performed by a pathologist to identify areas of tumor for enrichment by macrodissection. Tumor DNA was isolated and evaluated for the presence of KRAS codons 12, 13, 61, and 146 mutations using digital droplet PCR analysis.

DISCLAIMER

Test results should be interpreted in the context of clinical findings, family history, and other laboratory data. If results obtained do not match other clinical or laboratory findings, please contact the laboratory for possible interpretation. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.

Rare polymorphisms exist that could lead to false-negative or false-positive results.

This assay was designed to detect KRAS codon 12, 13, 61, and 146 mutations.

PATIENT NAME TESTINGKRASP, NORMAL

21-5208



1-800-533-1710

KRAS Somatic Mutation Analysis

KRASP

PATIENT NAME TESTINGKRASP, NORMAL				ORDER NUMBER K302000020
PATIENT ID R064475	DATE OF BIRTH 01/01/1991	AGE 30 Y	SEX Female	REQUESTED BY CLIENT CLIENT
COLLECTED 2/2/2021, 12:00 AM	RECEIVED 2/2/2021, 10:40 AM	REPORTED 2/18/2021, 12:53 PM		
The collected, received, and reported dates and times on the report are in the time zone of the performing location.				CLIENT ORDER NUMBER
VALIDC Test Validation's MML 35 characters City MN 123456789				CLIENT MRN R064475

A negative result does not rule out the presence of a mutation that may be present but below the limit of detection for this assay (approximately 0.1-0.5%).

TEST CLASSIFICATION

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

RELEASED BY

Kevin C. Halling, M.D., Ph.D.

Code : MCR Laboratory : Mayo Clinic Laboratories - Rochester Main Campus
Lab Director : WILLIAM G MORICE, II MD, PhD CLIA Certificate : 24D0404292

Address : 200 FIRST STREET SW
ROCHESTER MN 55905